Coherus Biosciences (CHRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Coherus Biosciences (CHRS) generates revenue through the sale of Loqtorzi and the promotion of its biosimilar pipeline. The company accumulates its primary capital via insurance reimbursements for the supply of affordable versions of high-cost biologics for oncology patients. The current EV/EBITDA ratio stands at 0.00. Detailed dynamics of this metric are available on the GURU.Markets platform, which features a price chart illustrating valuation trends.

This indicator determines the business value including net debt relative to operating profit before depreciation and amortization. The metric measures cash flow generation efficiency while remaining sensitive to debt load and tax obligations. By analyzing the EV/EBITDA valuation trend, an investor can identify signs of business contraction. For Coherus Biosciences (CHRS), this is critical due to a cash deficit driven by drug marketing costs and debt service obligations.